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Abstract
To analyze the characters of Down syndrome (DS) who failed to be diagnosed after prenatal screening and hope to be able to improve
theprogramsofprenatal screeningand reduce themisseddiagnosisofDS. In thismulticenter study,wecollected themissedcases from
3prenatal diagnosiscenters andanalyzed their characters. A total of 126DSbabies failed tobediagnosedafterprenatal screening. Their
mothers accepted the prenatal screening in second trimester. We collected the mothers’ blood and detected the levels of alpha-
fetoprotein (AFP) and the free beta subunit of human chorionic gonadotropin (fbhCG) by time-resolved fluoroimmunoassay. The values
were also presented as multiples of the median (MoM) and determined the risk of carrying a fetus with DS by Wallace LifeCycle Elipse
analysis software. Compared with normal control group, the level of fbhCG and hCGMoMwere dramatically increased, while AFP and
AFP MoM were decreased. The area under the receiver-operating-characteristic curve of trisomy 21 was 0.8387 for hCG-MoM and
AFP-MoM testing. The sensitivity, specificity, positive predictive value, and negative predictive value were 84.6%, 74.8%, 75.4%, and
83.6%, respectively. Meanwhile, the prediction mode was “0.39957+1.90897
∗
HCG-MOM3.32713∗AFP-MOM”. It was worthwhile
noting that the risk of 65.9%DSmisseddiagnosis groupwere higher than1/1000, 92.9%higher than1/3000.However, 72.5%cases in
normal control groupwere lower than 1/3000.Only 9.2%motherswould be higher than the value of risk in 1/1000. Thepredictionmode
of hCGMoMandAFPMoMmight beable tohelp us reduce themisseddiagnosis. It is alsonecessary toadjustmore reasonable rangeof
noninvasive prenatal testing with further clinical researches.
Abbreviations: AFP = alpha-fetoprotein, DR = rate of detection, DS = Down syndrome, fbhCG = free beta subunit of human
chorionic gonadotropin, FPR = false-positive rate, MoM = multiples of the median, NIPT = noninvasive prenatal testing, PAPP-A =
pregnancy-associated plasma protein A, ROC curve = receiver-operating characteristic curve, uE3 = unconjugated estriol.
Keywords: biomarkers, Down syndrome, missed diagnosis, prenatal diagnosis, prenatal screening, serum
1. Introduction 1959. The main pathogenesis of DS was that the chromosome 21Down syndrome (DS), also named as trisomy 21 syndrome, is one
of the most common chromosomal diseases with inheritedmental
disability. It was first described by LangDown in 1886, and it was
confirmed that the disease was caused by 3 chromosome 21 untilEditor: Farid Azmoudeh-Ardalan.
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1does not separate during meiosis. According to epidemiological
studies, the incidence of DS was about 1/700,[1] there were about
200 thousand cases increase in the global every year. Mental
retardation was the most prominent and serious problem, which
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[2]
Jiang et al. Medicine (2017) 96:24 Medicineearly onset Alzheimer’s disease. Most of the patients had
mental retardation, and abstract thinking ability was the most
serious injury.With the increase of age, low intelligence gradually
was more obvious. Recently, the survival time of DS has been
greatly improved due to the development of medical technology
and the enhancement of social and humanistic care. However, the
patient still could not take care of themselves, which bring heavy
mental and economic burden to the family and the society. The
problems concerning cognitive mental retardation have become
more important than those symptoms with DS.
Until now, there is a lack of effective treatments for DS.
Prenatal screening and diagnosis was an effective way to prevent
the birth of children with DS. In the past 3 decades, it has been
widely used worldwide[3,4] and achieved good achievement. The
most common prenatal screening method is a combination of
serum levels of alpha-fetoprotein (AFP), unconjugated estriol
(uE3), and the free beta subunit of human chorionic gonadotro-
pin (fbhCG) with maternal age in the second trimester.[5,6]
According to most researches, the rate of detection (DR) was
75% along with a 5% false-positive rate (FPR).[7] In China, the
DR was about 50% to 67% according to a multicenter
study.[8–10] Recently, more scholars suggested a new screening
method performed between 8 and 13 weeks of gestational age.[9]
This new test consists of the concentration of fbhCG and
pregnancy-associated plasma protein A (PAPP-A), ultrasound
measurement of nuchal translucency, and maternal age. Using
this screening program, 75% to 85% of fetuses of DS could be
detected with a FPR of 5%.[11–13] However, both the DR and
FPR of these methods were in need being improved.
Because of the technical limitations of the prenatal screening,
about 30% DS could not be found. In the present study, we have
collected the missed cases from 3 prenatal diagnosis centers and
analyzed their characters. With statistical analysis, we hope to be
able to improve the programs of prenatal screening and reduce
the missed diagnosis of DS.Table 1
The baseline parameters of 2 groups in this study.
DS missed
diagnosis group
Normal
control group P
N 126 131
Ethnicity (Chinese) 126 131
Singleton pregnancy 126 131
Maternal age, y 27.6±4.2 27.0±2.9 .132
Maternal weight, kg 57.2±7.9 58.6±8.7 .202
Gestational age, wk 17.0 (16.0–17.0) 17.2 (16.5–17.6) .054
15–16wk 11 (8.7%) 3 (2.3%)
16–17wk 40 (31.7%) 38 (29.0%)
17–18wk 48 (38.1%) 64 (48.9%)
≥18wk 27 (21.4) 26 (19.8%)
The normal distribution data were expressed as mean±SD. The abnormal distribution data were
expressed as median (P2.5–P97.5). DS = Down syndrome, SD = standard deviation.2. Materials and methods
2.1. Patients and design
This multicenter retrospective study was conducted in the
Changzhou Women and Children Health Hospital of Nanjing
Medical University, Nanjing Women and Children Health
Hospital of Nanjing Medical University, and Suzhou Municipal
Hospital (China). From October 2002 to June 2015, we found a
total of 126 babies of DS failed to be diagnosed in 3 centers after
follow-up. Their mothers all accepted the programs of prenatal
screening; however, we didn’t found the abnormalities in the
fetus. In present study, we took the 126 mothers as the research
object, collected and analyzed their clinical parameters. Mean-
while, 131 mothers who had normal babies were selected as the
normal control group. Both common parameters were shown
in Table 1. Among 126 cases, 6 mothers were older than 35;
however, they insisted on prenatal screening.
The study design and protocol were reviewed and approved by
the ethics committee of ChangzhouWoman and Children Health
Hospital affiliated to Nanjing Medical University.
3. Methods
3.1. Samples collected
All of the subjects received the prenatal screening in second
trimester after genetic counseling and informed consent.2According to the operating program of prenatal screen, we
collected the blood from every case in second trimester (15–20
weeks). Gestational age was calculated by each pregnant
woman’s last menstrual period or ultrasonography. An amount
of 3mL blood of all the cases were collected by simple needle
aspiration. After being placed 0.5 to 2 hours at room
temperature, the samples were centrifuged at 3000rpm for
5 minutes to remove cells. The serums were stored at 4 °C and the
levels of AFP, fbhCGwere detected within 7 days, then they were
long-stem stored at 80 °C.3.2. Prenatal screening in second trimester
As Miao et al[14] described, the levels of AFP and fbhCG were
quantified by time-resolved fluoroimmunoassay using Wallac
1235 AutoDELFIA (DELFIA1235: Perkin Elmer, Waltham,
MA). The value were also presented as multiples of the median
(MoM) and determined the risk of carrying a fetus with DS by
Wallace LifeCycle Elipse analysis software (Perkin Elmer) in the
second trimester.
High risk: T21>1/270, T18>1/350. Intermediate risk: T21
1/270 to 1/1000, T18 1/350 to 1/1000. Advanced age: maternal
age ≥35.3.3. Statistical analysis
The stratified analysis, the interaction test, covariate screening,
curve fitting, and the receiver-operating characteristic curve
(ROC curve) were performed using EmpowerStats 64 software
(X&Y solutions, Inc. Boston MA).[15]P< .05 was chosen to be
statistically significant. Results of parameters were expressed as
mean± standard deviation for continuous variables with normal
distribution median, 2.5th percentile, and 97.5th percentile for
the data with abnormal distribution. t test and nonparametric test
were employed to compare differences for continuous variables
between 2 groups.4. Results
In the past 13 years, a total of 126 DS babies have failed to be
diagnosed in 3 prenatal diagnosis centers of Jiangsu Province.
Their mothers accepted prenatal screening program. However,
we did not discover their abnormal risk.Meanwhile, 131mothers
were selected as the normal control group after follow-up. There
were no significant differences in maternal age, weight, and
Table 2
Compared the value of fbhCG and AFP between 2 groups.
DS missed diagnosis group Normal control group P
N 126 131
fbhCG, ng/mL 21.9 (15.5–30.6) 11.1 (7.8–16.6) <.001
hCG MoM 1.7 (1.2–2.1) 0.9 (0.6–1.2) <.001
AFP, U/mL 30.9 (23.1–40.2) 38.5 (31.8–50.4) <.001
AFP MoM 0.8 (0.6–1.0) 1.0 (0.8–1.2) <.001
The abnormal distribution data were expressed as median (P2.5–P97.5). AFP= alpha-fetoprotein, DS
= Down syndrome, fbhCG = free beta subunit of human chorionic gonadotropin, MoM = multiples of
the median.
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Figure 1. Compared the value of human chorionic gonadotropin-multiples of
the median (MoM) and alpha-fetoprotein-MoM between 2 groups.
Jiang et al. Medicine (2017) 96:24 www.md-journal.comgestational age between 2 groups, and their parameters were
shown in Table 1.
Compared with normal control group, the level of fbhCG and
hCGMoMwere significant increased, while AFP and AFPMoM
were decreased (Table 2). By regression analyzed after adjusted
for maternal age and weight, the odds ratios (ORs) and 95%
confidence intervals were shown in Table 3. hCG-MoM was one
of the dangerous factors in DS missed diagnosis (OR=5.35).
While the OR of AFP-MoM was 0.14. Because the fbhCG and
AFP were closely related to the gestational age, we divided the
cases into 2 groups according to the gestational week (17 weeks).
Regardless of gestational age less than 17 weeks or more than 17
weeks, we got the same results as above. The data of every group
were shown in Table 4. Meanwhile, Fig. 1 showed the scatter
diagram of hCG-MoM and AFP-MoM according to the
gestational week.Table 3
Association of fbhCG and AFP levels with Down’s syndrome
missed diagnosis events.
Total Odds ratios
∗
95% CI P
fbhCG, ng/mL 15.78 (10.24–25.20) 1.11 1.08–1.15 <.0001
hCG MoM 1.19 (0.75–1.76) 5.35 3.24–8.83 <.0001
AFP, U/mL 34.51 (27.11–44.70) 0.94 0.92–0.97 <.0001
AFP MoM 0.88 (0.69–1.12) 0.14 0.06–0.34 <.0001
AFP = alpha-fetoprotein, CI = confidence interval, fbhCG = free beta subunit of human chorionic
gonadotropin, MoM = multiples of the median.
∗
Adjust for: Age; weight. Odds ratios and 95% confidence intervals are presented to show the risk of
Down’s syndrome.
Table 4
Compared the value of fbhCG and AFP according to gestational
age.
DS missed
diagnosis group
Normal
control group P
<17wk 51 41
fbhCG, ng/mL 25.6 (18.7–35.4) 13.7 (8.0–19.3) <.001
hCG MoM 1.7 (1.1–2.1) 0.9 (0.5–1.2) <.001
AFP, U/mL 25.9 (21.0–34.2) 34.9 (30.8–43.2) <.001
AFP MoM 0.8 (0.6–1.0) 1.0 (0.8–1.1) .002
≥17wk 75 90
fbhCG, ng/mL 19.2 (14.2–26.3) 10.8 (7.6–14.1) <.001
hCG MoM 1.5 (1.2–2.1) 0.9 (0.6–1.2) <.001
AFP, U/mL 32.8 (26.0–42.5) 41.0 (32.5–53.5) <.001
AFP MoM 0.8 (0.6–1.0) 1.0 (0.8–1.2) <.001
The abnormal distribution data were expressed as median (P2.5–P97.5). AFP= alpha-fetoprotein, DS
= Down syndrome, fbhCG = free beta subunit of human chorionic gonadotropin, MoM = multiples of
the median.
Figure 2. Prediction performance of human chorionic gonadotropin-multiples
of the median (MoM) and alpha-fetoprotein-MoM for down syndrome
screening.
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Table 5
Compared the distribution of 2 groups according to DS-risk.
DS missed diagnosis group Normal control group
N 126 (100%) 131 (100%)
<300 5 (4.0%) 0 (0%)
300–500 34 (27.0%) 5 (3.8%)
500–1000 44 (34.9%) 7 (5.3%)
Total (<1000) 83 (65.9%) 12 (9.2%)
1000–2000 23 (18.3%) 15 (11.5%)
2000–3000 11 (8.7%) 9 (6.9%)
Total (<3000) 117 (92.9%) 36 (27.5%)
>3000 9 (7.1%) 95 (72.5%)
DS = Down syndrome.
Jiang et al. Medicine (2017) 96:24 MedicineBased on the changes of hCG-MoM and AFP-MoM, we
calculated their primary outcome for trisomy 21 screening by the
area under the ROC curve (AUC). As shown in Fig. 2, the AUC
for trisomy 21was 0.8387 by hCG-MoMandAFP-MoM testing.
The sensitivity, specificity, positive predictive value, and negative
predictive one were 84.6%, 74.8%, 75.4%, and 83.6%,
respectively. Meanwhile, the prediction mode was “0.39957+
1.90897
∗
HCG-MOM 3.32713∗AFP-MOM.”
The value of risk is the most important index in prenatal
screening program, so we analyzed the distribution of 2 groups
according to DS-risk. It was worthwhile noting that the risk of
65.9% DS in missed diagnosis group were higher than 1/1000,
92.9% higher than 1/3000. However, 72.5% cases in normal
control group were lower than 1/3000. Only 9.2% mothers
would be higher than the value of risk in 1/1000. Table 5 and
Fig. 3 showed the characteristic of DS-risk clearly.Figure 3. The distribution of 2 groups according to Down syndrome-risk.
45. Discussion
It is well known that prenatal screening can contribute to
avoidance the birth of DS. However, it needs improving greatly.
Because of the technical limitations of the prenatal screening,
about 30%DS would failed to be diagnosed. The error source of
prenatal screening test was related to many factors, including the
affected factors of the indexes of AFP, fbhCG, uE3, PAPP-A, the
population data which we used to calculated the risk, the
establishment of MoM, methodology selection, experimental
error, and so on. A local mathematical algorithm has been
calculated in order to improve the second trimester strategy of
prenatal screening for fetal aneuploidies. Currently, we calculat-
ed the risk by lifecycle4.0, which used the data of Caucasian
population because we still do not have the data of Chinese
pregnant women. However we still got the DR was 62.0% for
trisomies 21 in the second trimester, which was similar to other
studies.
In present study, we collected the DS whose mothers received
the prenatal screening program from 3 centers. A total of 126 DS
babies were unfortunately born after prenatal screening. Maybe
it helps to improve the effectiveness of prenatal screening by
analyzing the data of these cases better.
At first, we found that the level of fbhCG and hCGMoMwere
dramatically increased, while AFP andAFPMoMwere decreased
in DS missed diagnosis group. Although 2 indexes related to the
gestational week, we did not found these changes above were due
to the gestational age. In the common prenatal screening
program, we calculated the DS-risk combined with maternal
age, gestational week, the concentration of fbhCG, and AFP. We
have already considered the effectuation of the value hCGMoM
and AFP MoM to DS-risk. However, maybe we could make use
of them better to improve prenatal screening program. As you
can see, the area under the ROC for primary outcome of trisomy
21 screening was 0.8479. The sensitivity, specificity, positive
predictive value, and negative predictive value were 84.6%,
74.8%, 75.4%, and 83.6%, respectively. Meanwhile, we also got
a prediction mode which might be able to help us reduce the DS’s
missed diagnosis. We thought we should used the hCG-MoM,
AFP-MoM and the prediction model better to improve the
effectiveness of screening. However, whether it could be 1 index
for prenatal diagnosis still needs more validation by clinical data.
Second, the characteristic of the distribution according to DS-
risk was worthwhile noting. We found the risk of 65.9% in DS
missed diagnosis group were higher than 1/1000, 92.9% higher
than 1/3000. Only 9.2% normal mothers would be higher than
the value of risk in 1/1000. So in theory, if we adjust the cutoff of
prenatal diagnosis in 1/3000, we can find about 93% of the DS
fetus, but it will also make 27% of the normal mothers receive
unnecessary test.
Recently, noninvasive prenatal testing (NIPT) for common
fetal aneuploidies was proved to be a better prenatal screening
program, which was detected cell-free Deoxyribonucleic acid
obtained frommaternal plasma bymassively parallel sequencing.
Nowadays, NIPT was widely used in prenatal screen for T21,
T18, T13, and presented good accuracy.[16] The American
College of Obstetricians and Gynecologists,[17] International
Society for Prenatal Diagnosis[18] have issued the committee
opinions and guidelines about the clinical application of NIPT,
and they also recommend the patients of high risk group to accept
NIPT. In 2015, Chinese scholars firstly suggested the mothers
whose DS screening results were intermediate risk (1/300–1/
1000) to accept NIPT in order to reduce themissed diagnosis. The
[6] Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum screening for
Jiang et al. Medicine (2017) 96:24 www.md-journal.comviews and our results are consistent. If the mothers whose DS-risk
are higher than 1/1000 could accept NIPT, it could reduce the
birth of 65% DS cases. We can get higher DR by adjusting the
cut-off value to 1/3000, but it also brings more false positive
results. Therefore, the results of the study could contribute to
select the population of NIPT more reasonably and it is necessary
to adjust more reasonable range of NIPT with further clinical
researches.
In conclusion, we collected the missed DS cases from 3 prenatal
diagnosis center and analyzed their characters and found the
prediction mode of hCG MoM and AFP MoM might be able to
help us reduce the missed diagnosis. It is also necessary to adjust
more reasonable range of NIPT with further clinical researches.
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